Kraig Biocraft Laboratories Inc (KBLB)

[es1]

You bring up a very valid point Mojo

well the truth is kblb paid sigma in shares for their tech

Actually the truth is Sigma thought our shares were a better deal then cash. According to Manshoon Sigma took 1,029,412 shares for the rights to the ZFN for spider silk DNA. I dont think anyone can argue that.

So what does a ZFN cost?
And what does SIAL value our stock at?
Between $3-13 from what I can find. I am sure I am wrong....Right?? Maybe Manshoon or KB or someone can find better info but if they are paying 3 million to 13 million for ZFN rights Kim made out like a bandit for 1 million shares

Well I did a little digging but the info is pretty hard to find. Here is what I did find and I am sure SOMEONE will want to argue this but I am actually curious as to the answer to this question.
So argue away but I am not going to respond to opinion I am looking for links.

So to begin with this is what I can find...

Reference to the fact they are not cheap...couldnt find a price. Notice this is from Yale. If they say it is expensive it is.

Researchers
at Sangamo BioSciences have also developed a platform for
engineering ZFNs; although some details of this method have
been published8, implementation requires access to a proprietary
archive of engineered zinc-finger units9. Researchers may
purchase customized ZFNs made by the Sangamo approach
through the Sigma-Aldrich CompoZr service, but the cost of
these proteins9 limits the scale and scope of projects that can
be performed.

http://www.yale.edu/giraldezlab/Papers_files/Sander_CoDA2010.pdf

So what did Sigme pay Sagmo for the non medical ZFN license?

The expanded agreement provides Sigma-Aldrich with exclusive rights to develop and distribute ZFP-modified cell lines for commercial production of protein pharmaceuticals and ZFP-engineered transgenic animals for livestock, companion animals and therapeutic protein production. Sangamo retained all rights to ZFP-modified transgenic animals for discovery of novel therapeutics and the right to use ZFPs as therapeutic products. Under this agreement, Sigma-Aldrich will make initial payments of $20.0 million to Sangamo, consisting of an upfront license payment of $15.0 million and $5.0 million through the purchase of 636,133 shares of Sangamo common stock at market price. Market price is determined by the average closing price of Sangamo stock over the past 30 trading days, or $7.86 per share. Sangamo is eligible to earn additional contingent commercial license fees of up to $5.0 million based on certain conditions and thereafter a royalty based upon a percentage of net sales and sublicensing revenue. Sangamo is also eligible to receive commercial milestone payments ranging from $2.0 million to $10.0 million, up to a total of $25.0 million, based upon cumulative product sales.

http://investor.sigmaaldrich.com/releasedetail.cfm?ReleaseID=413513

Here are the few places that mention the cost of licensing ZFNs...

Shire (NASDAQ: SHPGY) will pay Sangamo (NASDAQ: SGMO) $13 million upfront for exclusive worldwide rights to Sangamo’s “zinc finger” protein technology to target up to seven genes to stop the bleeding disorders hemophilia A and B.

http://www.bizjournals.com/sanfrancisco/blog/biotech/2012/02/sangamo-shire-hemophilia-zinc-finger.html

Sangamo BioSciences, Inc. (Nasdaq: SGMO), the leading developer of zinc finger DNA-binding proteins (ZFPs), today announced an agreement to provide Pfizer Inc (NYSE: PFE) with a worldwide, non-exclusive license for the use of certain ZFP Nuclease (ZFNs) reagents to permanently eliminate the Glutamine Synthetase (GS) gene in Chinese Hamster Ovary (CHO) cell lines and for the use of these ZFN-modified cells for clinical and commercial production of therapeutic proteins. Under the terms of the agreement Sangamo will receive an upfront payment of $3.0 million from Pfizer for a fully paid license.

We have an exclusive commercial license agreement with Dow AgroSciences LLC (“DAS”), a wholly owned indirect subsidiary of Dow Chemical Corporation. Under this agreement, we are providing DAS with access to our proprietary zinc finger DNA-binding protein (ZFP) technology and the exclusive right to use our ZFP technology to modify the genomes or alter the nucleic acid or protein expression of plant cells, plants, or plant cell cultures. We have retained rights to use plants or plant-derived products to deliver ZFP transcription factors (ZFP TFs™) or zinc-finger nuclease (ZFN™) into human or animals for diagnostic, therapeutic, or prophylactic purposes.

Pursuant to the Research License and Commercial Option Agreement which we entered into in October 2005, DAS made an initial cash payment to us of $7.5 million. In November 2005, the Company sold approximately 1.0 million shares of common stock to DAS at a price of $3.85 per share, resulting in proceeds of $3.9 million. Our agreement with DAS provided for an initial three-year research term during which DAS agreed to pay Sangamo $6.0 million in research funding over the three-year period and make additional payments of up to $4.0 million in research milestone payments during this same period, depending on the success of the research program. We agreed to supply DAS and its sublicensees with ZFP TFs and/or ZFNs for both research and commercial use over the initial three year period of the agreement.

In June 2008, DAS exercised its option under the agreement to obtain a commercial license to sell products incorporating or derived from plant cells generated using our ZFP technology, including agricultural crops, industrial products and plant-derived biopharmaceuticals. The exercise of the option triggered a one-time commercial license fee of $6.0 million, payment of the remaining $2.3 million of the previously agreed $4.0 million in research milestones, minimum sublicensing payments totaling up to

http://www.wikinvest.com/stock/Sangamo_BioSciences_(SGMO)/Agreement_Dow_Agrosciences_Plant_Agriculture